Gut hormones, and short bowel syndrome: The enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation

World Journal of Gastroenterology

Volumn 12, Issue 26, 2006, Pages 4117-4129

  Martin, Gary R ^a   Beck, P L ^a   Sigalet, D L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Enteric nervous system; Epidermal growth factor; Glucagon like peptide 2; Gut hormones; Insulin like growth factor I; Intestinal adaptation; Intestinal mucosa; Parenteral nutrition; Short bowel syndrome; Total parenteral nutrition

Indexed keywords

ANTIINFLAMMATORY AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTROINTESTINAL HORMONE; GEFITINIB; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; HORMONE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MESSENGER RNA; PEPTIDE YY; SOMATOMEDIN C; TEDUGLUTIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALTERNATIVE RNA SPLICING; CARCINOGENESIS; CLINICAL TRIAL; COLITIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ENZYME INACTIVATION; HUMAN; INTESTINE ADAPTATION; INTESTINE MUCOSA; L CELL; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SHORT BOWEL SYNDROME; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

EID: 33748622556     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i26.4117     Document Type: Review

References (148)

1. Dowling RH, Booth CC. Structural and functional changes following small intestinal resection in the rat. Clin Sci 1967; 32: 139-149
2. Vanderhoof JA. Short bowel syndrome in children and small intestinal transplantation. Pediatr Clin North Am 1996; 43: 533-550
3. Williamson RC. Intestinal adaptation (first of two parts). Structural, functional and cytokinetic changes. N Engl J Med 1978; 298: 1393-1402
4. Sigalet DL. Short bowel syndrome in infants and children: an overview. Semin Pediatr Surg 2001; 10: 49-55
5. Vanderhoof JA, Langnas AN, Pinch LW, Thompson JS, Kaufman SS. Short bowel syndrome. J Pediatr Gastroenterol Nutr 1992; 14: 359-370
6. Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology 1997; 113: 1767-1778
7. Meehan JJ, Georgeson KE. Prevention of liver failure in parenteral nutrition-dependent children with short bowel syndrome. J Pediatr Surg 1997; 32: 473-475
8. Briones ER, Iber FL. Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. J Am Coll Nutr 1995; 14: 219-228
9. Baksheev L, Fuller PJ. Humoral factors in intestinal adaptation. Trends Endocrinol Metab 2000; 11: 401-405
10. Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am J Physiol 1993; 264: G179-G186
11. Lovshin J, Drucker DJ. New frontiers in the biology of GLP-2. Regul Pept 2000; 90: 27-32
12. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999; 117: 99-105
13. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997; 138: 4837-4843
14. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000; 85: 2884-2888
15. Martin GR, Wallace LE, Hartmann B, Holst JJ, Demchyshyn L, Toney K, Sigalet DL. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2005; 288: G431-G438
16. van Goudoever JB, Stoll B, Hartmann B, Holst JJ, Reeds PJ, Burrin DG. Secretion of trophic gut peptides is not different in bolus- and continuously fed piglets. J Nutr 2001; 131: 729-732
17. Burrin DG, Stoll B. Key nutrients and growth factors for the neonatal gastrointestinal tract. Clin Perinatol 2002; 29: 65-96
18. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004; 286: G964-G972
19. Burrin DG, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington RK, Schmidt M, Holst JJ, Hartmann B, Sangild PT. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1249-G1256
20. Burrin DG, Stoll B, Guan X, Cui L, Chang X, Holst JJ. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology 2005; 146: 22-32
21. Sigalet DL, Martin GR. Hormonal therapy for short bowel syndrome. J Pediatr Surg 2000; 35: 360-363; discussion 364
22. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998; 275: G911-G921
23. Warner BW. GLP-2 as therapy for the short-bowel syndrome. Gastroenterology 2001; 120: 1041-1043
24. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122: 531-544
25. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997; 273: E77-E84
26. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54: 1224-1231
27. Bloom SR. An enteroglucagon tumour. Gut 1972; 13: 520-523
28. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 1971; 12: 773-782
29. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93: 7911-7916
30. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997; 272: E1050-E1058
31. Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol 1997; 273: G1252-G1262
32. Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 1997; 273: G559-G563
33. Hartmann B, Thulesen J, Hare KJ, Kissow H, Orskov C, Poulsen SS, Holst JJ. Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept 2002; 105: 173-179
34. Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 2000; 21: 619-670
35. Alavi K, Schwartz MZ, Palazzo JP, Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000; 35: 847-851
36. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368-371
37. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718
38. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119: 1467-1475
39. Furuta M, Yano H, Zhou A, Rouille Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, Steiner DF. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 1997; 94: 6646-6651
40. Holst JJ. Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. Regul Pept 2000; 93: 45-51
41. Damholt AB, Buchan AM, Holst JJ, Kofod H. Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2. Endocrinology 1999; 140: 4800-4808
42. Dey A, Lipkind GM, Rouille Y, Norrbom C, Stein J, Zhang C, Carroll R, Steiner DF. Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon. Endocrinology 2005; 146: 713-727
43. Webb GC, Dey A, Wang J, Stein J, Milewski M, Steiner DF. Altered proglucagon processing in an alpha-cell line derived from prohormone convertase 2 null mouse islets. J Biol Chem 2004; 279: 31068-31075
44. Irwin DM, Wong J. Trout and chicken proglucagon: alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2. Mol Endocrinol 1995; 9: 267-277
45. Irwin DM. Molecular evolution of proglucagon. Regul Pept 2001; 98: 1-12
46. Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS, Mortensen PB. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000; 47: 370-376
47. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999; 45: 559-563
48. Caddy G, Johnston C, Ardill J, Pogue K, Collins J, Gardiner K, Watson P. Distribution of glucagon-like peptide-2 in normal colonic tissue. Scand J Gastroenterol 2003; 38: 798-799
49. Sham J, Martin G, Meddings JB, Sigalet DL. Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome. J Pediatr Surg 2002; 37: 765-769
50. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119: 744-755
51. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 2001; 98: 12497-12502
52. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005; 124: 105-112
53. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96: 1569-1573
54. Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 2001; 276: 21489-21499
55. Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, Drucker DJ. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 1999; 274: 30459-30467
56. Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol 2005; 19: 459-473
57. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61: 687-693
58. Rocha FG, Shen KR, Jasleen J, Tavakkolizadeh A, Zinner MJ, Whang EE, Ashley SW. Glucagon-like peptide-2: divergent signaling pathways. J Surg Res 2004; 121: 5-12
59. Jasleen J, Ashley SW, Shimoda N, Zinner MJ, Whang EE. Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro. Dig Dis Sci 2002; 47: 1135-1140
60. Bulut K, Meier JJ, Ansorge N, Felderbauer P, Schmitz F, Hoffmann P, Schmidt WE, Gallwitz B. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF-beta-mediated effect. Regul Pept 2004; 121: 137-143
61. Kim KA, Kakitani M, Zhao J, Oshima T, Tang T, Binnerts M, Liu Y, Boyle B, Park E, Emtage P, Funk WD, Tomizuka K. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 2005; 309: 1256-1259
62. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251-263
63. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001-1020
64. Potten CS, Owen G, Roberts SA. The temporal and spatial changes in cell proliferation within the irradiated crypts of the murine small intestine. Int J Radiat Biol 1990; 57: 185-199
65. Velazquez E, Ruiz-Albusac JM, Blazquez E. Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes. Eur J Biochem 2003; 270: 3001-3009
66. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000; 6: 802-807
67. Sayegh AI, Ritter RC. Vagus nerve participates in CCK-induced Fos expression in hindbrain but not myenteric plexus. Brain Res 2000; 878: 155-162
68. Sayegh AI, Ritter RC. CCK-A receptor activation induces fos expression in myenteric neurons of rat small intestine. Regul Pept 2000; 88: 75-81
69. Larsen PJ, Vrang N, Orskov C, Hartmann B, Holst JJ, Tang-Christensen M. The central glucagon-like peptide-2 (GLP-2) containing pathway is involved in regulation of food intake in rats. Obesity Research 2001; 9: 55S
70. Tang-Christensen M, Vrang N, Hartmann B, Larsen LK, Orskov C, Holst JJ, Larsen PJ. The correlation between feeding status and the amount of proglucagon, GLP-1 and GLP-2 in the central nervous system of the rat. Diabetes 2001; 50: A373
71. Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003; 27: 450-456
72. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Orskov C, Holst JJ, Poulsen SS. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 2002; 103: 9-15
73. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 2005; 128: 1340-1353
74. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997; 15: 673-677
75. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24
76. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294
77. Drucker DJ, Boushey RP, Wang F, Hill ME, Brubaker PL, Yusta B. Biologic properties and therapeutic potential of glucagon-like peptide-2. JPEN J Parenter Enteral Nutr 1999; 23: S98-100
78. Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA, Howarth GS. Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol 2005; 204: 687-692
79. Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 1992; 74: 379-284
80. Ruiz-Grande C, Pintado J, Alarcon C, Castilla C, Valverde I, Lopez-Novoa JM. Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol 1990; 68: 1568-1573
81. Tavares W, Drucker DJ, Brubaker PL. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 2000; 278: E134-E139
82. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999; 277: E937-E947
83. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999; 276: G79-G91
84. Tavakkolizadeh A, Shen R, Abraham P, Kormi N, Seifert P, Edelman ER, Jacobs DO, Zinner MJ, Ashley SW, Whang EE. Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis. J Surg Res 2000; 91: 77-82
85. Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004; 37: 385-400
86. Schmidt PT, Hartmann B, Bregenholt S, Hoist JJ, Claesson MH. Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Scand J Gastroenterol 2000; 35: 522-527
87. Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ, Hellstrom PM. Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. Eur J Gastroenterol Hepatol 2005; 17: 207-212
88. Chen K, Nezu R, Wasa M, Sando K, Kamata S, Takagi Y, Okada A. Insulin-like growth factor-1 modulation of intestinal epithelial cell restitution. JPEN J Parenter Enteral Nutr 1999; 23: S89-S92
89. Lund PK. Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system. Ann N Y Acad Sci 1998; 859: 18-36
90. Wang J, Niu W, Nikiforov Y, Naito S, Chernausek S, Witte D, LeRoith D, Strauch A, Fagin JA. Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J Clin Invest 1997; 100: 1425-1439
91. Vanderhoof JA, McCusker RH, Clark R, Mohammadpour H, Blackwood DJ, Harty RF, Park JH. Truncated and native insulinlike growth factor I enhance mucosal adaptation after jejunoileal resection. Gastroenterology 1992; 102: 1949-1956
92. Lund PK. Insulin-like growth factor I: molecular biology and relevance to tissue-specific expression and action. Recent Prog Horm Res 1994; 49: 125-148
93. Ney DM, Huss DJ, Gillingham MB, Kritsch KR, Dahly EM, Talamantez JL, Adamo ML. Investigation of insulin-like growth factor (IGF)-I and insulin receptor binding and expression in jejunum of parenterally fed rats treated with IGF-I or growth hormone. Endocrinology 1999; 140: 4850-4860
94. Rosenzweig SA. What's new in the IGF-binding proteins? Growth Horm IGF Res 2004; 14: 329-336
95. Albiston AL, Herington AC. Tissue distribution and regulation of insulin-like growth factor (IGF)-binding protein-3 messenger ribonucleic acid (mRNA) in the rat: comparison with IGF-I mRNA expression. Endocrinology 1992; 130: 497-502
96. Albiston AL, Taylor RG, Herington AC, Beveridge DJ, Fuller PJ. Divergent ileal IGF-I and IGFBP-3 gene expression after small bowel resection: a novel mechanism to amplify IGF action? Mol Cell Endocrinol 1992; 83: R17-R20
97. Ney DM. Effects of insulin-like growth factor-I and growth hormone in models of parenteral nutrition. JPEN J Parenter Enteral Nutr 1999; 23: S184-S189
98. Gillingham MB, Dahly EM, Murali SG, Ney DM. IGF-I treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2003; 284: R363-R371
99. Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995; 108: 564-580
100. Thompson JS. Epidermal growth factor and the short bowel syndrome. JPEN J Parenter Enteral Nutr 1999; 23: S113-S116
101. Helmrath MA, Shin CE, Erwin CR, Warner BW. The EGF\EGF-receptor axis modulates enterocyte apoptosis during intestinal adaptation. J Surg Res 1998; 77: 17-22
102. Shin CE, Helmrath MA, Falcone RA Jr, Fox JW, Duane KR, Erwin CR, Warner BW. Epidermal growth factor augments adaptation following small bowel resection: optimal dosage, route, and timing of administration. J Surg Res 1998; 77: 11-16
103. Shin CE, Falcone RA Jr, Duane KR, Erwin CR, Warner BW. The distribution of endogenous epidermal growth factor after small bowel resection suggests increased intestinal utilization during adaptation. J Pediatr Surg 1999; 34: 22-26
104. Helmrath MA, Shin CE, Fox JW, Erwin CR, Warner BW. Adaptation after small bowel resection is attenuated by sialoadenectomy: the role for endogenous epidermal growth factor. Surgery 1998; 124: 848-854
105. Stern LE, Erwin CR, O'Brien DP, Huang FS, Warner BW. Serum from mice after small bowel resection enhances intestinal epithelial cell growth. J Pediatr Surg 2001; 36: 184-189
106. O'Brien DP, Nelson LA, Williams JL, Kemp CJ, Erwin CR, Warner BW. Selective inhibition of the epidermal growth factor receptor impairs intestinal adaptation after small bowel resection. J Surg Res 2002; 105: 25-30
107. Helmrath MA, Erwin CR, Warner BW. A defective EGF-receptor in waved-2 mice attenuates intestinal adaptation. J Surg Res 1997; 69: 76-80
108. Juno RJ, Williams JL, Knott AW, Erwin CR, O'brien DP, Warner BW. A serum factor after intestinal resection stimulates epidermal growth factor receptor signaling and proliferation in intestinal epithelial cells. Surgery 2002; 132: 377-383
109. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132
110. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998; 95: 4386-4391
111. Stephens J, Stoll B, Guan XF, Helmrath M, Burrin D. Relative stimulation of superior mesenteric arterial (SMA) blood flow by enteral nutrition and glucagon-like peptide 2 (GLP-2) in piglets. Gastroenterology 2004; 126: A142
112. Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, Burrin DG. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 2003; 125: 136-147
113. Adrian TE, Thompson JS, Quigley EM. Time course of adaptive regulatory peptide changes following massive small bowel resection in the dog. Dig Dis Sci 1996; 41: 1194-1203
114. Del Olmo JCM, Caballero MAC, Alvarez JIB, Mena LA, Puerta CV. Decrease in plasma levels of vasoactive intestinal polypeptide in short bowel syndrome: Experimental study. International Surgery 1998; 83: 150-153
115. Lezoche E, Carlei F, Vagni V, Mora GV, Speranza V. Elevated plasma levels of vasoactive intestinal polypeptide in short bowel syndrome. Am J Surg 1983; 145: 369-370
116. Andrews NJ, Irving MH. Human gut hormone profiles in patients with short bowel syndrome. Dig Dis Sci 1992; 37: 729-732
117. Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 1982; 79: 2514-2518
118. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 417-418
119. El-Salhy M, Grimelius L, Wilander E, Ryberg B, Terenius L, Lundberg JM, Tatemoto K. Immunocytochemical identification of polypeptide YY (PYY) cells in the human gastrointestinal tract. Histochemistry 1983; 77: 15-23
120. El-Salhy M, Wilander E, Grimelius L, Terenius L, Lundberg JM, Tatemoto K. The distribution of polypeptide YY (PYY) - and pancreatic polypeptide (PP) - immunoreactive cells in the domestic fowl. Histochemistry 1982; 75: 25-30
121. Greeley GH Jr, Jeng YJ, Gomez G, Hashimoto T, Hill FL, Kern K, Kurosky T, Chuo HF, Thompson JC. Evidence for regulation of peptide-YY release by the proximal gut. Endocrinology 1989; 124: 1438-1443
122. Ali-Rachedi A, Varndell IM, Adrian TE, Gapp DA, Van Noorden S, Bloom SR, Polak JM. Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 1984; 80: 487-491
123. Bottcher G, Alumets J, Hakanson R, Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 1986; 13: 283-291
124. Savage AP, Gornacz GE, Adrian TE, Ghatei MA, Goodlad RA, Wright NA, Bloom SR. Is raised plasma peptide YY after intestinal resection in the rat responsible for the trophic response? Gut 1985; 26: 1353-1358
125. Suzuki T, Nakaya M, Itoh Z, Tatemoto K, Mutt V. Inhibition of interdigestive contractile activity in the stomach by peptide YY in Heidenhain pouch dogs. Gastroenterology 1983; 85: 114-121
126. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984; 30: 255-262
127. Adrian TE, Savage AP, Fuessl HS, Wolfe K, Besterman HS, Bloom SR. Release of peptide YY (PYY) after resection of small bowel, colon, or pancreas in man. Surgery 1987; 101: 715-719
128. Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998; 33: 828-832
129. Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999; 84: 2513-2517
130. Shibata C, Naito H, Jin XL, Ueno T, Funayama Y, Fukushima K, Hashimoto A, Matsuno S, Sasaki I. Effect of glucagon, glicentin, glucagon-like peptide-1 and -2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch. Scand J Gastroenterol 2001; 36: 1049-1055
131. Ljungmann K, Hartmann B, Kissmeyer-Nielsen P, Flyvbjerg A, Holst JJ, Laurberg S. Time-dependent intestinal adaptation and GLP-2 alterations after small bowel resection in rats. Am J Physiol Gastrointest Liver Physiol 2001; 281: G779-G785
132. Sigalet DL, Martin GR. Mechanisms underlying intestinal adaptation after massive intestinal resection in the rat. J Pediatr Surg 1998; 33: 889-892
133. Hill FL, Zhang T, Gomez G, Greeley GH Jr. Peptide YY, a new gut hormone (a mini-review). Steroids 1991; 56: 77-82
134. McCormack SA, Johnson LR. Role of polyamines in gastrointestinal mucosal growth. Am J Physiol 1991; 260: G795-G806
135. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001; 58: 244-258
136. Morgan DM. Polyamines. An overview. Mol Biotechnol 1999; 11: 229-250
137. Thomas T, Kiang DT. Additive growth-inhibitory effects of DL-alpha-difluoromethylornithine and antiestrogens on MCF-7 breast cancer cell line. Biochem Biophys Res Commun 1987; 148: 1338-1345
138. Johnson LR, McCormack SA. Healing of Gastrointestinal Mucosa: Involvement of Polyamines. News Physiol Sci 1999; 14: 12-17
139. Han X, Kazarinoff MN, Seiler N, Stanley BA. Rat colon ornithine and arginine metabolism: coordinated effects after proliferative stimuli. Am J Physiol Gastrointest Liver Physiol 2001; 280: G389-G399
140. Seidel ER, Scemama JL. Gastrointestinal polyamines and regulation of mucosal growth and function. J Nutr Biochem 1997; 8: 104-111
141. Wang JY, Johnson LR, Tsai YH, Castro GA. Mucosal ornithine decarboxylase, polyamines, and hyperplasia in infected intestine. Am J Physiol 1991; 260: G45-G51
142. Gobert AP, Cheng Y, Akhtar M, Mersey BD, Blumberg DR, Cross RK, Chaturvedi R, Drachenberg CB, Boucher JL, Hacker A, Casero RA Jr, Wilson KT. Protective role of arginase in a mouse model of colitis. J Immunol 2004; 173: 2109-2117
143. Meleagros L, Ghatei MA, Bloom SR. Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat. Gut 1994; 35: 1701-1706
144. Pillai RB, Tolia V, Rabah R, Simpson PM, Vijesurier R, Lin CH. Increased colonic ornithine decarboxylase activity in inflammatory bowel disease in children. Dig Dis Sci 1999; 44: 1565-1570
145. Antony T, Thomas T, Shirahata A, Thomas TJ. Selectivity of polyamines on the stability of RNA-DNA hybrids containing phosphodiester and phosphorothioate oligodeoxyribonucleotides. Biochemistry 1999; 38: 10775-10784
146. Thulesen J, Hartmann B, Hare KJ, Kissow H, Orskov C, Holst JJ, Poulsen SS. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004; 53: 1145-1150
147. Hamm-Alvarez SF. Focus on "EGF receptor downregulation depends on a trafficking motif in the distal tyrosine kinase domain". Am J Physiol Cell Physiol 2002; 282: C417-C419
148. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998; 12: 3663-3674